Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA OK's Lilly's Taltz; Rival To Novartis' Cosentyx

This article was originally published in Scrip

Executive Summary

In giving its blessing to Eli Lilly & Co. on March 22 to market Taltz (ixekizumab) as a treatment for adults with moderate-to-severe plaque psoriasis, the FDA created a new rivalry for Novartis AG's medicine Cosentyx (secukinumab).

You may also be interested in...



Lilly's Taltz Approved For AS As New Guidelines Keep TNF Inhibitors In Front Line

VP Rebecca Morison said the ankylosing spondylitis indication adds more evidence of Taltz's benefits. She noted Lilly believes there should be fewer steps before AS patients access IL-17 inhibitors.

Novartis Champions Cosentyx With More Long-Term Psoriasis Data

Although its focus may be shifting somewhat towards other indications, the Swiss major has reported study read-outs that demonstrate the long-term efficacy of its IL-17A inhibitor blockbuster in nail and palmoplantar psoriasis.

Novartis Has Blockbuster Targets For Cosentyx In New Autoimmune Indications

Next up for Cosentyx is psoriatic arthritis and ankylosing spondylitis. Novartis presented impressive long-term efficacy data at ACR in PsA and AS. Incoming CEO and Chief Medical Officer Vas Narasimhan said the company sees a blockbuster opportunity and is exploring the anti-TNF naïve market in AS.

Related Content

Topics

UsernamePublicRestriction

Register

SC064804

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel